Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Follicular 17Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 6Lymphoma 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 3Leukemia 3Neoplasms 2Bronchiolitis Obliterans Syndrome 2Tumor Lysis Syndrome 1Solid Tumors 1Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Indolent Non-Hodgkin's Lymphoma 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1Anemia 1

Interventions

zanubrutinib 2tirabrutinib 1obinutuzumab 1idelalisib 1Voriconazole 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × B-cell Malignancies × obinutuzumab × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡